Figure 1.

Patient flow diagram. *Liso-cel is composed of an equal target dose of CD8⁺ and CD4⁺ CAR⁺ T cells. While CAR⁺ T cells could be manufactured for all patients, 1 patient received nonconforming product. ^†This patient was discovered to have Richter transformation after leukapheresis and prior to receiving liso-cel and was included in the safety population but not the efficacy population, as Richter transformation was an exclusion criterion.